Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.34 |
| ▸ | STK16 | O75716 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.30 |
| ▸ | GPR6 | P46095 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376432 | 0.94 | JAK3 (0.35) | JAK3JAK2HCRTR2STK16FYN | |
| SCHEMBL1964412 | 0.89 | JAK3 (0.38) | JAK3JAK2HCRTR2STK16FYN | |
| SCHEMBL376743 | 0.84 | IRAK4 (0.46) | JAK3JAK2STK16FYNSRC | |
| SCHEMBL3230085 | 0.80 | EGFR (0.39) | JAK3JAK2STK16FYNSRC | |
| SCHEMBL376487 | 0.80 | JAK3 (0.44) | JAK3JAK2STK16FYNSRC | |
| SCHEMBL376654 | 0.79 | JAK3 (0.41) | JAK3JAK2STK16FYNSRC | |
| SCHEMBL384434 | 0.78 | USP30 (0.33) | JAK3JAK2BTK | |
| SCHEMBL376401 | 0.77 | PIK3CD (0.46) | JAK3JAK2BTKIRAK4 | |
| SCHEMBL377034 | 0.75 | ALDH1A1 (0.34) | HCRTR2IRAK4HCRTR1 | |
| SCHEMBL15203512 | 0.74 | JAK2 (0.40) | JAK3JAK2BTKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328890-B1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2328890-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | Pfizer Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | JAK3 1841/4885JAK2 1001/4885HCRTR2 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.